NCT03785249 2025-09-30Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1Mirati Therapeutics Inc.Phase 1/2 Active not recruiting731 enrolled 2 FDA
NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled
NCT02451553 2022-06-07Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary CancerUniversity of WashingtonPhase 1 Completed41 enrolled